Dermatite Atopique

Dupixent est le premier traitement à moduler spécifiquement les mécanismes immunitaires clés de la dermatite atopique en inhibant les signaux IL-4 et IL-13, principaux facteurs de l’inflammation de type 2.^1,2

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives⁸.

Dupixent est le premier traitement à moduler spécifiquement les mécanismes immunitaires clés de la dermatite atopique en inhibant les signaux IL-4 et IL-13, principaux facteurs de l’inflammation de type 2.^1,2

We are pleased to share this extract from our recent webinar on ‘New perspectives in the treatment of pediatrics patients with severe Atopic Dermatitis and adult patients with severe prurigo nodularis’ with you. Watch Prof. Christian Vestergaard as he offers a deep dive into Biologics and their Mode of Action pediatric AD.

We are pleased to share this extract from our recent webinar on ‘New perspectives in the treatment of pediatrics patients with severe Atopic Dermatitis and adult patients with severe prurigo nodularis’ with you. Watch Prof. Christian Vestergaard as he gives an insightful view on Disease modification in young children with AD.

Clinical challenges to achieve long-term disease control within treatment of moderate to severe AD.

3rd of December 2024

A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.

Speaker : Dr. Klas Agerberg, Uppsala University Hospital, Sweden